Anti-CLDN18_2 Antibody and an In Vitro Diagnostic Kit
AssigneeJiangsu Aosaikang Biopharmaceutical Co., Ltd.
InventorsYong WEN, Guwei HOU, Song FU, Jiye SUN
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to kits comprising an anti claudin 18.2 antibody that are useful for assessing expression claudin 18.2 expression in a biological sample obtained from a human, e.g., a human patient having cancer.
Claims16
A method of detecting claudin 18.2 (CLDN18.2) in a biopsy obtained from a human, comprising:
- contacting the biopsy with an anti-CLDN18.2 antibody or an antigen-binding fragment thereof comprising heavy chain CDR1-3 comprising SEQ ID NOs:1-3, respectively, and light chain CDR1-3 comprising SEQ ID NOs:4-6, respectively;
- and
- detecting the binding of the antibody or antigen-binding fragment to the biopsy, wherein the presence of binding is indicative of the presence of CLDN18.2 in the biopsy.
A method of diagnosing cancer in a human, comprising:
- contacting a biopsy from the human with an anti-CLDN18.2 antibody or an antigen-binding fragment thereof comprising heavy chain CDR1-3 comprising SEQ ID NOs:1-3, respectively, and light chain CDR1-3 comprising SEQ ID NOs:4-6, respectively;
- and
- detecting the binding of the antibody or antigen-binding fragment to the biopsy, wherein the presence of binding is indicative of the presence of cancer in the human.
A kit comprising an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment comprises heavy chain CDR1-3 comprising SEQ ID NOs:1-3, respectively, and light chain CDR1-3 comprising SEQ ID NOs:4-6, respectively.
Dependencies are inferred from the claim text.